company background image

Peptron KOSDAQ:A087010 Stock Report

Last Price


Market Cap







29 Jun, 2022


Company Financials
A087010 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health5/6

A087010 Stock Overview

Peptron, Inc. engages in the development of peptide-based medicines.

Peptron Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Peptron
Historical stock prices
Current Share Price₩9,940.00
52 Week High₩13,900.00
52 Week Low₩8,150.00
1 Month Change-3.02%
3 Month Change-3.02%
1 Year Change-23.24%
3 Year Change-39.94%
5 Year Change-59.92%
Change since IPO-52.21%

Recent News & Updates

Dec 25
Peptron's (KOSDAQ:087010) Stock Price Has Reduced 53% In The Past Five Years

Peptron's (KOSDAQ:087010) Stock Price Has Reduced 53% In The Past Five Years

Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...

Shareholder Returns

A087010KR Life SciencesKR Market

Return vs Industry: A087010 underperformed the KR Life Sciences industry which returned -7% over the past year.

Return vs Market: A087010 exceeded the KR Market which returned -25.6% over the past year.

Price Volatility

Is A087010's price volatile compared to industry and market?
A087010 volatility
A087010 Average Weekly Movement6.7%
Life Sciences Industry Average Movement7.4%
Market Average Movement6.2%
10% most volatile stocks in KR Market10.8%
10% least volatile stocks in KR Market3.9%

Stable Share Price: A087010 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: A087010's weekly volatility (7%) has been stable over the past year.

About the Company

1997n/aHo-Il Choi

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson’s and Alzheimer’s disease.

Peptron Fundamentals Summary

How do Peptron's earnings and revenue compare to its market cap?
A087010 fundamental statistics
Market Cap₩205.03b
Earnings (TTM)-₩11.88b
Revenue (TTM)₩8.60b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A087010 income statement (TTM)
Cost of Revenue₩2.20b
Gross Profit₩6.39b
Other Expenses₩18.28b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-576.14
Gross Margin74.37%
Net Profit Margin-138.21%
Debt/Equity Ratio15.0%

How did A087010 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is A087010 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A087010?

Other financial metrics that can be useful for relative valuation.

A087010 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue21.9x
Enterprise Value/EBITDA-21x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A087010's PS Ratio compare to its peers?

A087010 PS Ratio vs Peers
The above table shows the PS ratio for A087010 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.5x
A220100 FutureChemLtd
A245620 Eone Diagnomics Genome Center
A039860 NanoenTek
A087010 Peptron

Price-To-Sales vs Peers: A087010 is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (7.5x).

Price to Earnings Ratio vs Industry

How does A087010's PE Ratio compare vs other companies in the KR Life Sciences Industry?

Price-To-Sales vs Industry: A087010 is expensive based on its Price-To-Sales Ratio (23.8x) compared to the KR Life Sciences industry average (4.3x)

Price to Sales Ratio vs Fair Ratio

What is A087010's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A087010 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A087010's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of A087010 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A087010's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A087010's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A087010's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Peptron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Peptron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Peptron's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Peptron performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A087010 is currently unprofitable.

Growing Profit Margin: A087010 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A087010 is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.

Accelerating Growth: Unable to compare A087010's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A087010 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (18.8%).

Return on Equity

High ROE: A087010 has a negative Return on Equity (-19.71%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Peptron's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A087010's short term assets (₩31.1B) exceed its short term liabilities (₩6.2B).

Long Term Liabilities: A087010's short term assets (₩31.1B) exceed its long term liabilities (₩9.0B).

Debt to Equity History and Analysis

Debt Level: A087010 has more cash than its total debt.

Reducing Debt: A087010's debt to equity ratio has increased from 3.8% to 15% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A087010 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A087010 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 6.4% each year.

Discover healthy companies


What is Peptron current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A087010's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A087010's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A087010's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A087010's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A087010 has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Ho-Il Choi

no data


Mr. Ho-Il Choi serves as the Chief Executive Officer of Peptron, Inc.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Peptron, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Peptron, Inc.
  • Ticker: A087010
  • Exchange: KOSDAQ
  • Founded: 1997
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩205.031b
  • Shares outstanding: 20.63m
  • Website:


  • Peptron, Inc.
  • 37-24, Yuseong-daero 1628 beon-gil
  • Yuseong-gu
  • Daejeon
  • 340-54
  • South Korea


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.